Artelo Biosciences (ARTL) Other Non-Current Assets (2021 - 2025)
Artelo Biosciences (ARTL) posted quarterly Other Non-Current Assets of $3000.0 for Q4 2025, little changed year-over-year from $3000.0 in Q4 2024, and little changed quarter-over-quarter from $3000.0 in Q3 2025.
Artelo Biosciences (ARTL) Other Non-Current Assets (2021 - 2025) Analysis & Trends
Artelo Biosciences (ARTL) has reported Other Non-Current Assets for 5 consecutive years, with $3000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $3000.0; the TTM figure through Dec 2025 stood at $3000.0 (changed 0.0% YoY), while the FY2025 annual figure was $3000.0, changed 0.0% from the prior year.
- Other Non-Current Assets was little changed at $3000.0 in Q4 2025 per ARTL's latest filing, from $3000.0 in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $197000.0 in Q2 2023 and bottomed at $3000.0 in Q2 2022.
- Historically, Other Non-Current Assets has averaged $26750.0 across 5 years, with a median of $3000.0 in 2022.
- Annual changes were most pronounced in 2023 — Other Non-Current Assets jumped 6466.67% — and 2024, when it sank 98.48%.
- Artelo Biosciences' Other Non-Current Assets stood at $189000.0 in 2021, then plunged by 98.41% to $3000.0 in 2022, then changed by 0.0% to $3000.0 in 2023, then changed by 0.0% to $3000.0 in 2024, then changed by 0.0% to $3000.0 in 2025.
- Business Quant data shows ARTL's Other Non-Current Assets at $3000.0 in Q4 2025, $3000.0 in Q3 2025, and $3000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Artelo Biosciences | 107,735.40 | -492,264.60 | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 3,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |
| Sep 30, 2024 | 3,000.00 |
| Jun 30, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 3,000.00 |
| Jun 30, 2023 | 197,000.00 |
| Mar 31, 2023 | 3,000.00 |
| Dec 31, 2022 | 3,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Aug 31, 2021 | 189,000.00 |